BRIGHT and LanzaTech have partnered to develop technology converting carbon emissions into valuable products through a new biofoundry.
Quiver AI Summary
BRIGHT, the Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition at the Technical University of Denmark, has partnered with LanzaTech Global, Inc. to enhance technologies that convert carbon emissions into valuable products. This multi-year collaboration, running until April 2028, will establish a next-generation C1 biofoundry at DTU, leveraging LanzaTech’s synthetic biology expertise and BRIGHT’s facilities. The project aims to reduce industrial emissions through gas fermentation, where microbes convert CO₂, CO, and methane into useful materials. The partnership will also provide advanced tools for strain development and innovation in sustainable solutions. This initiative positions Denmark and Europe as key players in carbon-to-value biotechnology, with the goal of driving innovation in the circular bioeconomy.
Potential Positives
- Partnership with LanzaTech enables the design and installation of a state-of-the-art C1 biofoundry at DTU, enhancing research capabilities in carbon-to-value biotechnology.
- This collaboration positions Denmark and Europe as key players in the emerging field of circular bioeconomy, accelerating innovation and the transition to sustainable solutions.
- LanzaTech's expertise in synthetic biology will drive advancements in converting carbon emissions into valuable products, supporting industry sustainability goals.
Potential Negatives
- None
FAQ
What is the purpose of the BRIGHT and LanzaTech partnership?
The partnership aims to accelerate technologies converting carbon emissions into valuable products through advanced biotechnology.
What technologies will the new biofoundry utilize?
The biofoundry will utilize gas fermentation to transform CO₂, CO, and methane into fuels, chemicals, and materials.
How long will the partnership between BRIGHT and LanzaTech last?
The partnership will run for multiple years, specifically until April 2028.
What advantages does the C1 biofoundry provide?
The C1 biofoundry enables faster strain development, reduced innovation risk, and integration of AI-driven design tools for efficient research.
Where is the new biofoundry being established?
The new biofoundry is being established at the Technical University of Denmark (DTU) within the BRIGHT research center.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LNZA Insider Trading Activity
$LNZA insiders have traded $LNZA stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LNZA stock by insiders over the last 6 months:
- OF NEW ZEALAND SUPERANNUATION GUARDIANS has made 2 purchases buying 969,858 shares for an estimated $4,300,000 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$LNZA Revenue
$LNZA had revenues of $28M in Q4 2025. This is an increase of 132.74% from the same period in the prior year.
You can track LNZA financials on Quiver Quantitative's LNZA stock page.
$LNZA Hedge Fund Activity
We have seen 6 institutional investors add shares of $LNZA stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRW SECURITIES, LLC added 11,661 shares (+inf%) to their portfolio in Q4 2025, for an estimated $160,455
- VANGUARD GROUP INC added 2,780 shares (+4.7%) to their portfolio in Q4 2025, for an estimated $38,252
- MILLENNIUM MANAGEMENT LLC removed 1,943 shares (-9.8%) from their portfolio in Q4 2025, for an estimated $26,735
- GEODE CAPITAL MANAGEMENT, LLC added 595 shares (+4.6%) to their portfolio in Q4 2025, for an estimated $8,187
- ROYAL BANK OF CANADA removed 382 shares (-83.4%) from their portfolio in Q4 2025, for an estimated $5,256
- UBS GROUP AG removed 294 shares (-21.6%) from their portfolio in Q1 2026, for an estimated $4,706
- MORGAN STANLEY removed 249 shares (-98.4%) from their portfolio in Q4 2025, for an estimated $3,426
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Full Release
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- BRIGHT, the Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition at the Technical University of Denmark (DTU) and LanzaTech Global, Inc. (NASDAQ: LNZA ) (“LanzaTech”), a global leader in gas fermentation, have entered a multi-year agreement to accelerate development of technologies that convert carbon emissions into valuable products.
The partnership runs until April 2028 and includes the design and installation of a next-generation C1 biofoundry at DTU. This allows LanzaTech to extend its world-class synthetic biology expertise, leveraging BRIGHT’s infrastructure, talent, and regional reach. At the same time, DTU will gain the tools and expertise needed to establish Denmark and Europe as an important player in the emerging field of carbon-to-value biotechnology, accelerating innovation in the field of circular and competitive bioeconomy.
“DTU has a history of driving innovation from the lab to commercial deployment. Our new partnership with LanzaTech emphasizes our commitment to accelerate bio-solutions innovation for the benefit of Denmark, Europe and beyond,” says DTU provost, Christine Nellemann.
From carbon emissions to sustainable products
The new biofoundry will utilize gas fermentation where microbes transform CO₂, CO and methane into fuels, chemicals and materials. The technology is emerging as a key pathway for reducing industrial emissions and enabling circular, climate-positive solutions. Engineering these specialized microbes is, however, difficult, requiring advanced automation, AI, robotics, gas-handling and high-throughput strain-development tools.
“This partnership brings unique capabilities to Denmark and accelerates our ambition to turn carbon emissions into valuable products. Working with LanzaTech strengthens our ability to drive sustainable innovation with real impact,” says Luuk van der Wielen, Director of BRIGHT.
LanzaTech has spent more than 15 years developing world-leading synthetic biology capabilities for carbon-fixing, gas-fermenting organisms, including the first dedicated biofoundry for these challenging microbes. LanzaTech’s unique biofoundry solution is purpose built for non-model organisms with highly customized anaerobic and gas handling capabilities and advanced workflows validated through many years of operation.
“We are delighted to partner with BRIGHT, whose vision, expertise, and commitment to transformative research make them the ideal partner for LanzaTech. This marks a significant milestone in our transformation. By creating a dedicated team that consolidates our biotechnology know-how, we can focus the broader team on our commitment to delivering commercial sustainable aviation fuel and biorefining projects,” says LanzaTech CEO, Jennifer Holmgren.
Under the new agreement, a LanzaTech team will develop tailored methods and workflows for BRIGHT’s research missions, provide a non-exclusive license to relevant IP for tools and biofoundry workflows, and design and install a customized C1 biofoundry at DTU.
FACTS
Why this partnership matters
Recent advances in C1 biofoundry design at LanzaTech have created new opportunities to develop production strains more efficiently, enabling conversion of CO, CO₂ and methane off-gases into valuable fuels, chemicals and materials. Access to these capabilities is currently limited, slowing research and technology development worldwide.
Establishing a next-generation C1 biofoundry at BRIGHT will close this gap and create a shared platform for researchers, partners and innovation activities in Denmark and across Europe.
A C1 biofoundry specialized in microbes that utilize C1 gases will enable:
-
Faster strain development cycles
Automation and parallelization allow thousands of microbial designs to be generated and tested at once. -
Reduced innovation risk
High-throughput workflows enable testing many more variants, helping teams fail faster and optimize sooner. -
Integration of AI-driven design tools
Data from large-scale strain screening feeds into models that guide the next design cycle, accelerating the Design–Build–Test–Learn loop. -
Safe, high-precision research on challenging organisms
Working with non-model, often anaerobic microbes — and with flammable or toxic gases — requires specialized equipment and know-how.
About BRIGHT
BRIGHT is a research center at the Technical University of Denmark (DTU) focused on enabling transformative research and innovation for a circular and competitive bioeconomy. Through cutting-edge science, leading research infrastructure, interdisciplinary collaboration and strong industry partnerships, BRIGHT develops next-generation biological solutions for foods, materials and chemicals.
About LanzaTech
LanzaTech (NASDAQ: LNZA) is a leader in carbon management, using its proprietary gas-fermentation platform to transform waste carbon into valuable products. Through global partnerships, LanzaTech enables the production of feedstocks for high-value markets including SAF and chemicals. Headquartered in the U.S., the company provides technology and commercial pathways that strengthen industrial resilience and unlock new economic value from carbon.
